PPARD and laryngotracheoesophageal cleft: Thus, using the β-catenin inhibitor XAV-939 and PPARδ inhibitor GSK3787 to target the CXCR4 β-catenin/ PPARδ cascade attenuated EMT, which might serve as a potential therapy for LC treatment [369].